Frank P. McCormick

Known for his research on the fundamental differences between normal cells and cancer cells that allow development of novel therapeutic strategies, in areas that include: p21-Ras and other oncogenes, p53 and other tumor suppressors, protein kinases, and neurofibromatosis. After an early research career in the biotechnology industry (1981-92), Frank founded and directed a successful biotech company (Onyx Pharmaceuticals; 1992-96), and then moved into academia as Director of the Helen Diller Family Comprehensive Cancer Center and Cancer Research Institute of the University of California, San Francisco (1997-present). In 2013 took the position as Scientific Director of the Leidos/Frederick National Laboratory for Cancer Research National Ras Program.